Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma

被引：0
|
作者：
McNulty, M. [1 ]
Dean, A. [2 ]
Das, A. [1 ]
Gordon, M. [1 ]
机构：
[1] St John God Hosp Subiaco, Perth, WA, Australia
[2] St John God Hosp Subiaco, Subiaco, WA, Australia
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 147
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Shuling Chen
    Jiaxin Li
    Aoran Dong
    Zelong Liu
    Meiyan Zhu
    Meng Jin
    Guangyan Wei
    Shuang Wu
    Yan Wang
    Yong Chen
    Zhenwei Peng
    Journal of Hematology & Oncology, 16
  • [32] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [33] Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
    Rogers, Jane E.
    Mizrahi, Jonathan D.
    Xiao, Lianchun
    Mohindroo, Chirayu
    Shroff, Rachna T.
    Wolff, Robert
    Varadhachary, Gauri R.
    Javle, Milind M.
    Overman, Michael
    Fogelman, David R.
    Raghav, Kanwal P. S.
    Pant, Shubham
    McAllister, Florencia
    CANCER MEDICINE, 2020, 9 (15): : 5406 - 5415
  • [34] Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma
    Nebot-Villacampa, Maria-Jose
    Zafra-Morales, Ricardo
    Alfaro-Olea, Ascension
    Marin-Gorricho, Raquel
    Casajus-Navasal, Andrea
    Uriarte-Pinto, Moises
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (03) : 603 - 611
  • [35] NAB-PACLITAXEL as third-line therapy after failure of gemcitabine and 5-FU based combinations in advanced gall bladder cancer patients
    Manana, S. Singh
    Goel, V.
    Talwar, V.
    Raina, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis
    Zhang, Yiyin
    Xu, Jin
    Hua, Jie
    Liu, Jiang
    Liang, Chen
    Meng, Qingai
    Ni, Quanxing
    Shi, Si
    Yu, Xianjun
    JOURNAL OF CANCER, 2019, 10 (18): : 4420 - 4429
  • [37] Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
    Riedl, Jakob M.
    Posch, Florian
    Horvath, Lena
    Gantschnigg, Antonia
    Renneberg, Felix
    Schwarzenbacher, Esther
    Moik, Florian
    Barth, Dominik A.
    Rossmann, Christopher H.
    Stotz, Michael
    Schaberl-Moser, Renate
    Pichler, Martin
    Stoger, Herbert
    Greil, Richard
    Djanani, Angela
    Schlick, Konstantin
    Gerger, Armin
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 3 - 13
  • [38] Successful Treatment with Nab-Paclitaxel and Gemcitabine after FOLFIRINOX Failure in a Patient with Metastasized Pancreatic Adenocarcinoma
    Berger, Anne K.
    Weber, Tim F.
    Jaeger, Dirk
    Springfeld, Christoph
    ONKOLOGIE, 2013, 36 (12): : 763 - 765
  • [39] FOLFIRINOX and gemcitabine/nab-paclitaxel efficacy in the treatment of locally advanced unresectable pancreatic adenocarcinoma.
    Bednar, Filip
    Ocuin, Lee Mayer
    Steve, Jennifer
    Zenati, Mazen S.
    Winters, Sharon
    Hogg, Melissa Ellen
    Bahary, Nathan
    Zeh, Herbert J.
    Zureikat, Amer H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [40] Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis
    Schlick, Konstantin
    Gantschnigg, Antonia
    Seymer, Alexander
    Huemer, Florian
    Greil, Richard
    Weiss, Lukas
    CANCER MEDICINE, 2023, 12 (16): : 16997 - 17004
12345